摘要
目的探讨多柔比星联合顺铂化疗对宫颈癌放疗患者的疗效及对相关基因蛋白表达的影响。方法选取60例宫颈癌患者,按照随机数表法分为观察组和对照组,每组30例。两组患者均给予放疗治疗,对照组加用顺铂化疗,观察组加用多柔比星联合顺铂化疗。观察两组患者治疗前后He La细胞脆性组氨酸三联体(FHIT)蛋白、淋巴细胞瘤-2相关X(Bax)蛋白、Ki-67蛋白的表达情况,比较两组的临床疗效、生存率、不良反应发生率。结果治疗后,两组He La细胞FHIT、Bax蛋白表达均增高,观察组的表达水平均高于对照组(P<0.05);治疗后,两组He La细胞Ki-67蛋白表达均降低,但观察组的表达水平低于对照组(P<0.05)。观察组与对照组的总有效率分别为83.33%、60.00%,观察组临床疗效优于对照组(P<0.05);观察组患者的3、5年生存率均高于对照组患者(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论多柔比星联合顺铂对宫颈癌患者有良好的治疗效果,有效增加He La细胞FHIT、Bax蛋白的表达,降低Ki-67蛋白的表达,提高患者生存率,且不增加患者的不良反应发生率,是一种安全有效的治疗手段。
Objective To explore the effect of chemotherapy with doxorubicin combined with cisplatin on efficacy and protein expressions of related genes in cervical cancer patients undergoing radiotherapy. Methods Sixty patients with cervical cancer were divided into observation group and control group using the random number table, with 30 cases in each group. Both groups were treated with radiotherapy. Additionally, the control group received chemotherapy with cisplatin, and the observation group received chemotherapy with cisplatin and doxorubicin. The fragile histidine triad （FHIT） protein, B-cell lymphoma-2 associated X （Bax） protein and Ki-67 protein expressions of HeLa cells before and after treatment were observed in both groups. The clinical efficacy, survival rate and incidence rate of adverse effects were compared between the two groups. Results After treatment, FHIT protein and Bax protein expressions of HeLa cells increased in both groups, but the expression levels in the observation group were higher than those in the control group （ P 〈 0.05 ）. After treatment, Ki-67 protein expression of HeLa ceils in both groups decreased, but the expression level in the observation group was lower than that in the control group （P 〈 0.05 ）. The total effective rates of the observation group and control group were 83.33% and 60.00% respectively, and the clinical efficacy of the observation group was superior to that of the control group （ P 〈 0.05 ）. The three-year and five-year survival rates in the observation group were higher than those in the control group（P 〈 0.05 ）. There was no significant difference in the incidence rate of adverse reactions between the two groups （P 〉 0.05 ）. Conclusion Doxorubicin combined with cisplatin obtains a good efficacy for the treatment of cervical cancer, and can effectively increase the expressions of FHIT and Bax proteins and reduce the expression of Ki-67 protein in the HeLa cells. Moreover,it can improve the survival rate of patients and does not increase the incidence rate of adverse reactions, so it is a safe and effective therapeutic approach.
出处
《广西医学》
CAS
2016年第9期1256-1259,共4页
Guangxi Medical Journal
